June 11, 2020 / 12:47 PM / a month ago

BRIEF-Magenta Therapeutics Inc - Made Strategic Decision To Discontinue Enrollment In Phase 2 Study Of Mgta-456 In Inherited Metabolic Disorders

Magenta Therapeutics Inc:

* MAGENTA THERAPEUTICS PROVIDES PORTFOLIO UPDATE: STEM CELL MOBILIZATION AND CONDITIONING PROGRAMS PRIORITIZED AND ADVANCING TOWARD CLINICAL MILESTONES

* MAGENTA THERAPEUTICS INC - MGTA-145 FIRST-LINE MOBILIZATION PROGRAM TO MOVE INTO PHASE 2 STUDIES IN AUTOLOGOUS AND ALLOGENEIC PATIENTS IN 2020

* MAGENTA THERAPEUTICS INC - MGTA-117 ANTIBODY-DRUG CONJUGATE (ADC)-BASED CONDITIONING PROGRAM ON TRACK FOR INITIAL CLINICAL DATA IN 2021

* MAGENTA THERAPEUTICS INC - MADE STRATEGIC DECISION TO DISCONTINUE ENROLLMENT IN PHASE 2 STUDY OF MGTA-456 IN INHERITED METABOLIC DISORDERS

* MAGENTA THERAPEUTICS INC - ENROLLMENT IN PHASE 2 INVESTIGATOR-INITIATED TRIAL IN PATIENTS WITH BLOOD CANCERS IS EXPECTED TO BE COMPLETED

* MAGENTA THERAPEUTICS INC - TO DISCONTINUE ENROLLMENT IN PHASE 2 STUDY IN IMDS DUE TO ENROLLMENT CHALLENGES, PARTICULARLY DURING COVID-19 PANDEMIC

* MAGENTA THERAPEUTICS - TO DISCONTINUE ENROLLMENT IN PHASE 2 STUDY IN IMDS, DUE TO CHALLENGES OF ALLOGENEIC STEM CELL TRANSPLANT IN IMDS PATIENTS

* MAGENTA THERAPEUTICS - TO DISCONTINUE ENROLLMENT IN PHASE 2 STUDY IN IMDS, ALSO DUE TO FEEDBACK FROM FDA ON ENDPOINTS AND CLINICAL TRIAL DESIGN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below